PCI 7 November 2023, 15:22
Thermofisher: Thu 29 February 2024, 11:15
BMG Labtech: Wed 18 September 2024, 11:55
Owen Mumford 12 January 2022, 16:46

Current Edition

Cell and Gene Therapy

Upcoming Events

NextGen BioMed – 04/02/2025
BioTrinity 2025 – January 30th 2025
Elrig R&I 2025 – 27th January 2025
Biotechnology Show 2025: 20th January 2025
Anglonordic: 16th January 2025
AI in Drug Discovery – SAE media – January 14th 2025

Advertisement

Fujifilm rectangle: Fri 22 November 2024, 14:23
Roald Dahl Charity: Fri 15 November 2024, 12:57
A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault: Wed 17 July 2024, 11:46
Aurisco – 04/02/2025

Adagio pledges to press forward with COVID drug as CEO to resign

Dive Brief:

  • Adagio Therapeutics CEO Tillman Gerngross has agreed “in principle” to resign as head of the COVID-19 drug developer amid confusion over whether its most advanced antibody treatment works against the omicron variant.

 

  • The company’s board of directors plans to appoint current chief operating officer David Hering, a former Pfizer executive who joined Adagio last summer, as interim CEO, according to a Feb. 18 statement from Adagio, which plans to provide more information in “the near term.”

 

  • Adagio, which Gerngross co-founded in 2020 as a spinout of his company Adimab, raised nearly $800 million on the promise it could develop a better antibody medicine for COVID-19. That work has led to ADG20, the company’s lead candidate now in late-stage testing. But doubts of its potential emerged in December, when Adagio said the drug was much weaker against omicron than expected, a position it has since qualified.

 

Dive Insight:

Gerngross built Adagio with threats like omicron in mind, aiming to use Adimab’s technology and antibodies it licensed from the privately held company to develop a medicine that could work against different coronaviruses as well as different strains. The company parlayed that plan into an unusually fast ascent, going public a year after its founding in one of 2021’s largest initial stock offerings.

In late November, soon after omicron’s emergence, Adagio expressed confidence ADG20 would work well, noting that the mutations which made the variant more concerning weren’t associated with escape from the drug’s grasp.

That made the company’s Dec. 14 announcement of a 300-fold reduction in ADG20’s ability to neutralize omicron compared to other strains more surprising. Shares in Adagio collapsed, erasing roughly $3 billion in market capitalization.

Adagio stopped recruiting new study volunteers into two late-stage studies in response as it discussed updates to the trial plans with regulators.

By January, however, the company attempted to recalculate its assessment of ADG20’s potential. Subsequent laboratory studies by other groups found that, while neutralization was reduced versus omicron, the drug did retain some activity.

In a new statement Monday, Adagio said it will analyze clinical data for the 300 mg dose being tested in its two late-stage trials, results that should be available in March. Additionally, the company plans to evaluate higher doses of the drug, as well as explore modifying it to better bind to omicron.

Adagio said it may also develop new antibody drug candidates for use as a standalone treatment or in combination.

Notably, however, the company said that ADG20 has “markedly reduced neutralization activity” against the BA.2 lineage of omicron, the potential impact and spread of which is currently unclear.

Other antibody drug developers have struggled to keep up with variants, too. The U.S. government stopped distribution of treatments from Regeneron and Eli Lilly due to their reduced effectiveness versus omicron, although the Food and Drug Administration recently approved a new Lilly antibody drug that’s meant to work better.

Shares in Adagio rose by 2.5% on Tuesday morning.

Newcells 3 June 2024, 15:12
Novonordisk: Wed 17 July 2024, 11:22
FujiFilm 30 October 2023, 16:23
Autoscribe Mon 26 June 2023, 15:15
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
GenXPro: Mon 16 September 2024, 10:40